According to the current analysis of Emergen research, the global Follicular Lymphoma Treatment Market was valued at USD 2.08 billion in 2019 and is expected to reach USD 3.73 billion by 2027, at a CAGR of 7.6%. The global follicular lymphoma treatment market is growing with a lucrative CAGR owing to the growing demand for therapy, increasing innovation in newer drug development, favorable government financial support, and assistance for research and development focusing on treatment. Follicular lymphoma treatment has high demand; therefore, research centers and market players are investing a substantial amount in R&D. Furthermore, various treatment options for FL are mainly on the severity of symptoms associated with it. On the basis of various studies, there have been incidences where patients managed with an active surveillance approach have survival outcomes identical to those who receive early treatment.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/51
The report is updated with the latest impact of the novel coronavirus pandemic on the market. The pandemic has drastically altered the market dynamics and trends and demands. It has also disrupted the supply chain and generated financial difficulties. The report covers the comprehensive effect of the pandemic on the industry and offers an initial and future impact assessment of the impact of the COVID-19 pandemic on the Follicular Lymphoma Treatment business sphere.
According to Leukemia & Lymphoma Society, in 2019, about 82,310 new cases of lymphoma and 8,110 & 74,200 cases of Hodgkin & Non-Hodgkin Lymphoma (NHL), respectively, are were diagnosed in the U.S. Additionally, out of 30 NHL subtypes, follicular lymphoma contributes around 20 to 30% of the cases making it the most common form. In the western world, the number is equal to 20% of all lymphomas. Considering the new therapies that are coming up to combat the disease, Monoclonal antibodies can act more directly than chemotherapy agents. It is another active area of research across the globe.
Top players profiled in the report include:
AbbVie, Inc., Celgene, Bayer AG, Bristol Myers Squibb and Company, Epizyme Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Merck & Co. Inc., and Novartis AG.
Newly approved drugs and clinical trial pipeline of follicular lymphoma therapeutics holds a promising future. Furthermore, the shift from cytotoxic to targeted and immunotherapeutic agents is expected to provide traction to the market. Although follicular lymphoma remains incurable, recently approved immunotherapeutic agents have shown the overall extended survival for the patient. The drugs that are approaching completion, rising awareness among healthcare providers will together contribute to the escalated demand. After the approval of rituximab, many novel medications emerged to treat follicular lymphoma.
For instance, Obinutuzumab has recently been included in the Australian Pharmaceutical Benefits Scheme for application in first-line, advanced follicular lymphoma. The clinical outcomes show drastic changes with the emergence of enhanced first-line treatment in recent years. In case of recurrence of the disease, stem cell transplant may be a treatment option. These advantages are anticipated to considerably propel the market over the forecast period. Treatment patterns do not differ considerably in Asia from Western countries. The design of epidemiology is likely to shift with better healthcare. However, stringent regulatory policies for drug approval, coupled with the high cost of treatment, remains a major market restraint in low economic countries.
Request a discount on the report @ https://www.emergenresearch.com/request-discount/51
Key highlights from the report
- The North America follicular lymphoma treatment market is anticipated to dominate the global market. The growth is attributed to the rising demand for first-line therapy, high medical reimbursement facilities, and technological advancement in countries such as the U.S and Canada.
- The targeted therapy is expected to register significant market share among the other segments. This is attributed to the widespread application coupled with efficient healthcare outcomes. The diagnostic methods are improved, and the public and health care professionals are well aware of the potential benefits of targeted therapy impacting the growth.
- The market is driven by rapid product approval. For instance, in June 2020, The U.S. Food and Drug Administration (FDA) approved tazemetostat for relapsed or refractory follicular lymphoma (FL) for adults. The clinical pipeline also shows positive results, which would further propel the market in the near future.
- The combination drug therapy is an upcoming trend in the market. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved lenalidomide (REVLIMID) in combination with rituximab (RITUXAN) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL).
- Research organizations are expected to be the largest segment for the follicular lymphoma treatment market during the forecast period. The growth is contributed to its wide application in the research field. Non-Hodgkin’s lymphoma is one of the most common cancers worldwide. In recent years, much research have been carried out to find the most apt therapy.
Emergen research have segmented into the global follicular lymphoma treatment market on the basis of treatment, route of administration, end use, and region:
Treatment Outlook (Revenue, USD million; 2017-2027)
- Monoclonal Antibodies
- Targeted therapy
- Chemotherapy
- Radiation therapy
- Stem cell transplant
- Alkylating Agents
- Nucleoside Analogues
- Anthracycline Derivatives
- Others
To know more about the report, visit @ https://www.emergenresearch.com/industry-report/follicular-lymphoma-treatment-market
Route of Administration Outlook (Revenue, USD million; 2017-2027)
- Oral
- Parenteral
- Others
End Use Outlook (Revenue, USD million; 2017-2027)
- Hospitals
- Oncology Centers
- Ambulatory Care Centers
- Academic Research Institutes
- Others
Regional Outlook (Revenue, USD million; 2017-2027)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
The report further analyses the key factors that influence the growth of the top players of the market and their market share and global position. The report also covers market share, production value, gross margin analysis, import and export ratio, consumption and production patterns, SWOT analysis, Porter’s Five Forces analysis, feasibility analysis, and investment return analysis. Furthermore, detailed regional segmentation is offered to understand the operations of the key market players, market segments, and overall market scenario.
Request customization of the report @ https://www.emergenresearch.com/request-for-customization/51
Key Offerings of the Report:
- Detailed overview of market dynamics including drivers, restraints, opportunities, challenges, and growth prospects
- Analysis of the key strategic initiatives and competitive landscape including mergers & acquisitions, joint ventures, collaborations, product launches, and brand promotions, and partnerships, among others
- Comprehensive analysis of the industry outlook and analysis of the industrial chain
- Market forecast based on global, regional, and country-level market analysis
- Competitive landscape benchmarking
- In-depth analysis of the key market players with their product portfolios, financial positions, unique selling points, market share and size, and a comprehensive overview of their business
Thank you for reading this report. For further details or inquiries, please connect with us, and our team will ensure the report is tailored to meet your requirements.
About Emergen Research
At Emergen Research, we believe in advancing with technology. We are a growing Marketresearch and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Facebook | LinkedIn | Twitter | Blogs
Latest Reports: Smart Dust Market, Emulsifiers Market
Trending Reports: Soil Testing Equipment Market, Video Doorbell Market
Explore More Emergen Research Reports @
Directed Energy Weapons Market
Interoperability Solutions in Healthcare Market
Explosion Proof Equipment Market
Automotive Refinish Coatings Market
Surface Treatment Chemicals Market
Renewable Polypropylene Market
Driver Monitoring Systems Market